Shares in Neurizon Therapeutics Ltd are down about 45% over the past 12 months, but according to the team at Morgans, there is potentially good upside in the stock.
The broker has revisited Neurizon because the company released three news announcements in quick succession earlier this month.
Neurizon said that during his career, Dr Bremer had been involved in more than US$1 billion worth of licensing transactions.
3 sentences from our version of the report,
chosen to cover it. Nothing here is written; every line is in the article below.
How
Summarized version
Shares in Neurizon Therapeutics Ltd are down about 45% over the past 12 months, but according to the team at Morgans, there is potentially good upside in the stock.
The report’s most important sentence, shortened and in plain words. How
Headline check
Headline as published: Could this ASX biotech really jump more than 150%? One broker thinks so
The one thing this headline claims is in the report.
Figures, names and quoted words in the headline, looked for in the report itself — not in the summary above. One claim in this headline could be checked, so this is a narrow pass and not a thorough one. How this is checked
The article, shortened and in plain language
Shares in Neurizon Therapeutics Ltd are down about 45% over the past 12 months, but according to the team at Morgans, there is potentially good upside in the stock.
Morgans has just released a new research report on the company and reiterated its share price target on the company, to get to shortly.
The broker has revisited Neurizon because the company released three news announcements in quick succession earlier this month.
The most impactful of these was the hiring of a new Chief Executive Officer, Dr Chris Bremer, who has more than 20 years' leadership experience spanning drug development, portfolio strategy, commercialisation, and business development.
Neurizon said that during his career, Dr Bremer had been involved in more than US$1 billion worth of licensing transactions.
Neurizon's lead investigational therapy, NUZ-001, is being evaluated as a treatment for ALS in 250 participants.
Their unrisked valuation is $1.50 per share, while should the clinical trial be a failure, the valuation drops to 1 to 2 cents.
Shortened to 1 minute
of reading, this version reads 7.5 on the Niral Score.
You are reading our version, not theirs.
This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with
verdicts and loaded words taken out. Plain description stays, and so do adjectives
that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations
are theirs — quotations are never edited — and the indicators beside it measure
this version. Hover or tap Adjectives to see every one left in the text.
How outlets headlined it
Each outlet's own headline. Struck through: the loaded words our version leaves out. Plainest first.
The Motley Fool AustraliaThis ASX biotech could jump more than 30%, one broker saysplain
The Motley Fool AustraliaCould this ASX biotech really jump more than 150%? One broker thinks so1 change
Readers can ask a question about this story here.
Questions and answers are for subscribers.
Sign in
to read them.
Comments are read before they appear where anything in them needs a person to look.
Nothing posted here is ever deleted; a comment taken down keeps its text and the reason,
so the decision can be looked at again. How this works